No correlation was observed between vitamin D levels and disability of patients with multiple sclerosis between latitudes 18° and 30° South

Fragoso, Yára Dadalti; Adoni, Tarso; Alves-Leon, Soniza Vieira; Apóstolos‐Pereira, Samira Luísa; Arruda, Walter Oleschko; Brooks, Joseph Bruno Bidin; Cal, Henrique S. Rodrigues; Damasceno, Carlos A. Albuquerque; Gama, Paulo Diniz da; Gonçalves, Marcus Vinícius Magno; Jesus, Carlos César Lopes de; Machado, Suzana C. Nunes; Mansur, Letícia F.; Matta, André Palma da Cunha; Mendes, Maria Fernanda; Morales, Rogerio Rizo; Nobrega-Jr, Adaucto Wanderley da; Parolin, Mônica Koncke Fiuza; Peres, Mario Pietro; Ribeiro, Marlise de Castro; Ruocco, Heloisa Helena; Scherpenhuijzen, Simone; Siquinelli, Fabio; Stoney, Patrick N.; Varela, Daniel; Eboni, Audred C. Biondo; Spessotto, Caroline Vieira; Rocha, Elisa Teixeira da; Lacerda, Pamela Emanuele

doi:10.1590/0004-282x20160173

Cited by 9 publications

(4 citation statements)

References 38 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, vitamin D status was not associated with the level of MS patients’ disability expressed by EDSS. In addition, other authors have provided similar results [ 44 , 45 ]. However, Brola et al indicated a statistically significant connection between vitamin D serum levels and relapse instances, as well as the level of disability in MS patients [ 46 ].…”

Section: Discussionsupporting

confidence: 72%

Radiological Benefits of Vitamin D Status and Supplementation in Patients with MS—A Two-Year Prospective Observational Cohort Study

et al. 2023

View full text Add to dashboard Cite

Current data emphasize the immunomodulating role of vitamin D in enhancing the anti-inflammatory response. Vitamin D deficiency is an established risk factor for developing multiple sclerosis—the autoimmune demyelinating and degenerative disease of the central nervous system. Several studies confirmed that higher vitamin D serum level is associated with better clinical and radiological outcomes in patients with multiple sclerosis, whereas vitamin D supplementation benefits in multiple sclerosis remain inconclusive. Despite that, many experts suggest regular measurements of vitamin D serum levels and supplementation in patients with multiple sclerosis. In this study, 133 patients with multiple sclerosis (relapsing–remitting subtype) were prospectively observed in a 0-, 12- and 24-month time span in a clinical setting. The study group consisted of 71.4% of patients (95 out of 133) supplementing vitamin D. The associations between vitamin D serum levels, clinical outcomes (disability status expressed by EDSS, number of relapses and time to relapse) and radiological outcomes (new T2-weighted lesions and number of gadolinium-enhanced lesions) were evaluated. There were no statistically significant correlations between clinical outcomes and vitamin D serum levels or supplementations. Fewer new T2-weighted lesions were observed in patients with vitamin D supplementations (p = 0.034) in 24 months of observation. Moreover, an optimal or higher level of vitamin D (>30 ng/mL) maintained throughout the entire observation period was associated with a lower number of new T2-weighted lesions in 24 months of observation (p = 0.045). These results support vitamin D implementation commencement and amelioration in patients with multiple sclerosis.

show abstract

Section: Discussionsupporting

confidence: 72%

Radiological Benefits of Vitamin D Status and Supplementation in Patients with MS—A Two-Year Prospective Observational Cohort Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This finding was in accord with previous studies showing that serum 25(OH)D levels were not associated with the EDSS in demyelinating diseases such as MS and NMOSD. 24,32 Additionally, there was no association between serum 25(OH)D levels and ON attack severity (nadir BCVA) in our autoimmune-ON affected eyes as observed in disease activity in other autoimmune disorders such as SLE and RA. 33,34 These studies reported no associations between serum 25(OH)D levels and SLE Disease Activity Index (SLEDAI) in SLE or serum 25(OH)D levels and 3-variable Disease Activity Score (DAS28) in RA.…”

mentioning

confidence: 58%

“…The present study reported that serum 25(OH)D levels were not associated with ON attack severity (nadir BCVA) in NMOSD-ON affected eyes, in accord with previous studies describing a dissociation between serum 25(OH)D levels and the Expanded Disability Status Scale (EDSS) in NMOSD. 24 , 32 However, this result was inconsistent with studies in Korean and Chinese subjects, which evaluated serum 25(OH)D3 levels and their association with EDSS in NMOSD subjects. 11 , 23 The difference in the form of vitamin D measured [25(OH)D3 vs 25(OH)D] might explain the differences seen compared with our study.…”

Section: Discussionmentioning

confidence: 96%

Serum Vitamin D Levels and Status in Thai Optic Neuritis Subjects: A Case-Control Study

Puangsricharoen¹,

Vanikieti²,

Jindahra³

et al. 2022

OPTH

View full text Add to dashboard Cite

Objective To measure serum total vitamin D or 25-hydroxyvitamin D [25(OH)D] levels and status in immune-based optic neuritis (ON) including neuromyelitis optica spectrum disorder (NMOSD)-ON, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)-ON, autoimmune-ON, and idiopathic-ON and compare them with age- and sex-matched healthy controls. The secondary objective was to analyze the association between serum 25(OH)D levels and ON attack severity (nadir best-corrected visual acuity; nadir BCVA). Materials and Methods This was a single-center, case–control study. We enrolled 59 subjects (19 NMOSD-ON, 6 MOGAD-ON, 11 autoimmune-ON, 23 idiopathic-ON) diagnosed with acute immune-based ON (any ON attacks) over 11 years. Electronic medical records were reviewed and demographic data (age at sampling, sex, aquaporin-4 immunoglobulin (AQP4-IgG); myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG); other biomarkers of autoimmune disorders), ON attack severity (nadir BCVA), and serum 25(OH)D levels in the acute phase of ON were collected. Serum 25(OH)D levels of 236 age- and sex-matched healthy controls were assessed. Results Mean serum 25(OH)D levels were significantly lower in each group of immune-based ON compared with healthy controls ( p < 0.001 for each ON group). However, mean serum 25(OH)D levels were not significantly different between four ON groups (NMOSD-ON, 20.18±5.90 ng/mL; MOGAD-ON, 23.07±4.94 ng/mL; autoimmune-ON, 21.14±5.29 ng/mL; idiopathic-ON, 19.56 ±5.12 ng/mL; p = 0.525). All immune-based ON subjects had vitamin D insufficiency or vitamin D deficiency. The prevalences of vitamin D insufficiency and vitamin D deficiency were significantly higher than in healthy controls in each ON group (both p < 0.05 in each ON group). No associations were observed between serum 25(OH)D levels and ON attack severity (nadir BCVA). Conclusions Thai immune-based ON subjects had lower serum 25(OH)D levels and higher prevalence of vitamin D insufficiency and vitamin D deficiency compared with age- and sex-matched healthy controls. Serum 25(OH)D levels were not associated with ON attack severity (nadir BCVA). We highly recommend that serum 25(OH)D levels be screened in all subjects with acute immune-based ON.

show abstract

“…However not every study has reported association between vitamin D levels and MS. Fragoso et al in his study demonstrated that MS patients and control group had no significant differences between their vitamin D levels [ 16 ]. Some studies, focused on the disease activity, proved no interconnection between vitamin D and MS. Rito et al in his study showed that there is no link between EDSS scores and vitamin D levels [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Association Between Serum Vitamin D Levels and Frequency of Relapses in Patients With Multiple Sclerosis

Mansoor

Kumar²,

Kumar³

et al. 2021

Cureus

View full text Add to dashboard Cite

Introduction Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system affecting the myelin sheath of neurons with a wide range of symptoms. Among various risk factors studied that can increase the relapse, vitamin D is also a potential risk factor. In this study, we will determine the association between vitamin D status and frequency of relapses in patients with MS. Material and methods Seventy-four (74) patients with a confirmed diagnosis of MS, with more than one (01) relapse per year, for a minimum of two years, were included in the case group. Seventy-four (74) participants with a confirmed diagnosis of MS with one (01) or no relapse per year, for a minimum of two years, were included in the control group. After informed consent, the patient blood was drawn via phlebotomy and was sent to the lab for vitamin D levels. Results The mean serum vitamin D level was significantly lower in case group compared to control group (18.21 ± 4.21 ng/mL vs. 29.21 ± 5.72 ng/mL; p-value: < 0.0001). The number of participants with vitamin D level less than 30 ng/mL were significantly higher in patients with case group compared to control group (78.37% vs. 50.0%; p-value: 0.0003) Conclusion In this study, patients with more relapses per year had low level of serum vitamin D. There is emerging strong evidence that vitamin D plays an important role in the pathogenesis, progression, and disease burden of autoimmune disease, including MS.

show abstract

No correlation was observed between vitamin D levels and disability of patients with multiple sclerosis between latitudes 18° and 30° South

Cited by 9 publications

References 38 publications

Radiological Benefits of Vitamin D Status and Supplementation in Patients with MS—A Two-Year Prospective Observational Cohort Study

Radiological Benefits of Vitamin D Status and Supplementation in Patients with MS—A Two-Year Prospective Observational Cohort Study

Serum Vitamin D Levels and Status in Thai Optic Neuritis Subjects: A Case-Control Study

Association Between Serum Vitamin D Levels and Frequency of Relapses in Patients With Multiple Sclerosis

Contact Info

Product

Resources

About